IMGN

ImmunoGen Stock Price

3.60
0.045 (1.27%)
3.60
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
ImmunoGen Inc IMGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.045 1.27% 3.60 17:15:01
Close Price Low Price High Price Open Price Previous Close
3.60 3.52 3.71 3.55 3.555
Bid Price Ask Price Spread News
3.53 3.68 0.15 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
7,591 1,446,690 $ 3.63 $ 5,250,145 2,123,212 1.95 - 7.07
Last Trade Time Type Quantity Stock Price Currency
17:33:04 1 $ 3.65 USD

ImmunoGen Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 628.35M 174.54M 155.64M $ 82.27M $ -65.31M -0.70 -9.62
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

ImmunoGen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IMGN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week3.863.893.433.581,466,624-0.26-6.74%
1 Month3.784.503.383.821,942,559-0.18-4.76%
3 Months4.864.903.383.991,894,850-1.26-25.93%
6 Months3.705.403.014.152,169,298-0.10-2.7%
1 Year2.757.071.954.242,471,3580.8530.91%
3 Years7.6613.411.655.672,648,313-4.06-53.0%
5 Years9.7814.221.515.572,312,844-6.18-63.19%

ImmunoGen Description

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.


Your Recent History
NASDAQ
IMGN
ImmunoGen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.